Towards Novel Radiosensitizing Agents: The Role of Cytosolic PLA2α in Combined Modality Cancer Therapy

• Ringborg U , BergqvistD, BrorssonBet al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001—summary and conclusions. Acta Oncol. 42, 357–365 (2003).
   PubMed Web of Science ®Google Scholar
• Elshaikh M , LjungmanM, Ten Haken R, Lichter AS. Advances in radiation oncology. Annu. Rev. Med.57, 19–31 (2006).
   PubMed Web of Science ®Google Scholar
• James D , CoxKKA. Radiation Oncology: Rationale, Technique, and Results. Mosby Elsevier, PA, USA (2010).
   Google Scholar
• S⊘ren M , BentzenPMH, WolfgangT, MehtaMP (Eds). Radiation Oncology advances. Springer, Chicago, IL, USA (2008).
   Google Scholar
• Clamon G , HerndonJ, CooperR, ChangAY, RosenmanJ, GreenMR. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.J. Clin. Oncol.17(1), 4–11 (1999).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM . Brain tumors.N. Engl. J. Med.344(2), 114–123 (2001).
   PubMed Web of Science ®Google Scholar
• Riely GJ , MillerVA. Vascular endothelial growth factor trap in non-small-cell lung cancer.Clin. Cancer Res.13(15, pt 2), S4623–S4627 (2007).
   PubMed Web of Science ®Google Scholar
• Wong ET , BremS. Taming glioblastoma: targeting angiogenesis.J. Clin. Oncol.25(30), 4705–4706 (2007).
   PubMed Web of Science ®Google Scholar
• Suh JH , BarnettGH. Brachytherapy for brain tumor.Hematol. Oncol. Clin. North Am.13(3), 635–650 (1999).
   PubMed Web of Science ®Google Scholar
• Lee JH , MachtayM, KaiserLRet al. Non-small cell lung cancer: prognostic factors in patients treated with surgery and postoperative radiation therapy. Radiology 213(3), 845–852 (1999).
   PubMed Web of Science ®Google Scholar
• Wagner H Jr. Postoperative adjuvant therapy for patients with resected non-small cell lung cancer: still controversial after all these years. Chest117(4)(suppl 1), 110S–118S (2000).
   PubMed Web of Science ®Google Scholar
• Valerie K , YacoubA, HaganMPet al. Radiation induced cell signaling: inside–out and outside–in. Mol. Cancer Ther. 6, 789–801 (2000).
   Google Scholar
• Wei TK , ZhouH, IvanovVNet al. Mechanism of radiation-induced bystander effects: a unifying model. J. Pharm. Pharmacol. 60(8), 943–950 (2008).
   PubMed Web of Science ®Google Scholar
• Oehler C , DickinsonDJ, Broggini-TenzerAet al. Current concepts for the combined treatment modality of ionizing radiation and with anticancer agents. Curr. Pharm. Design 13(5), 519–535 (2007).
   PubMed Web of Science ®Google Scholar
• Ma BB , BristowRG, KimJ, SiuLL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents.J. Clin. Oncol.21, 2760–2776 (2003).
   PubMed Web of Science ®Google Scholar
• Thomlinson RH , GrayLH. The histological structure of some human lung cancers and the possible implications for radiotherapy.Br. J. Cancer9, 539–549 (1955).
   PubMed Web of Science ®Google Scholar
• Brown JM , GiacciaAJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.Cancer Res.58, 1408–1416 (1998).
   PubMed Web of Science ®Google Scholar
• Vaupel P , KelleherDK, HockelM. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy.Semin. Oncol.28, 29–35 (2001).
   PubMed Web of Science ®Google Scholar
• Overgaard J , HansenHS, OvergaardMet al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5–85. Radiother. Oncol. 46(2), 135–146 (1998).
   PubMed Web of Science ®Google Scholar
• Simpson JR , BauerM, PerezCAet al. Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 16(6), 1483–1491 (1989).
   PubMed Web of Science ®Google Scholar
• Komarnicky LT , PhillipsTL, MartzKet al. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int. J. Radiat. Oncol. Biol. Phys. 20(1), 53–58 (1991).
   PubMed Web of Science ®Google Scholar
• Eschwège F , Sancho-GarnierH, ChassagneDet al. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 39(2), 275–281 (1997).
   PubMed Web of Science ®Google Scholar
• Lee DJ , CosmatosD, MarcialVAet al. Results of an RTOG phase III trial (RTOG 85–27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 32(3), 567–576 (1995).
   PubMed Web of Science ®Google Scholar
• Le QT , McCoyJ, WilliamsonSet al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004), a Southwest Oncology Group study. Clin. Cancer Res. 10(16), 5418–24 (2004).
   PubMed Web of Science ®Google Scholar
• Rischin D , PetersL, FisherRet al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 23(1), 79–87 (2005).
   PubMed Web of Science ®Google Scholar
• Reddy SB , WilliamsonSK. Tirapazamine: a novel agent targeting hypoxic tumor cells.Expert Opin. Investig. Drugs18(1), 77–87 (2009).
   PubMed Web of Science ®Google Scholar
• Jaffe N , PaedD, TraggisD, SalianS, CassadyJR. Improved outlook for Ewing’s sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy.Cancer38, 1925–1930 (1976).
   PubMed Web of Science ®Google Scholar
• Bernier J . Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology?Nat. Clin. Pract. Oncol.2, 305–314 (2005).
   PubMedGoogle Scholar
• Calais G , AlfonsiM, BardetEet al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl Cancer Inst. 91(24), 2081–2086 (1999).
   PubMed Web of Science ®Google Scholar
• Schaake-Koning C , van den BogaertW, DalesioOet al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med.326(8), 524–530 (1992).
   PubMed Web of Science ®Google Scholar
• Rose PG , BlessingJA, GershensonDM, McGeheeR. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.J. Clin. Oncol.17(9), 2676–2680 (1999).
   PubMed Web of Science ®Google Scholar
• Macdonald JS , SmalleySR, BenedettiJet al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(10), 725–730 (2001).
   PubMed Web of Science ®Google Scholar
• Stupp R , HegiME, MasonWPet al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Bonner JA , HarariPM, GiraltJet al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11(1), 21–28 (2010).
   PubMed Web of Science ®Google Scholar
• Buzdar AU , IbrahimNK, FrancisDet al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23(16), 3676–3685 (2005).
   PubMed Web of Science ®Google Scholar
• Kim ES , HirshV, MokTet al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST), a randomised phase III trial. Lancet 372(9652), 1809–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Miles DW , ChanA, DirixLYet al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28(20), 3239–47 (2010).
   PubMed Web of Science ®Google Scholar
• Levy AP , LevyNS, WegnerS, GoldbergMA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia.J. Biol. Chem.270(22), 13333–13340 (1995).
   PubMed Web of Science ®Google Scholar
• Shweiki D , NeemanM, ItinA, KeshetE. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis.Proc. Natl Acad. Sci. USA92(3), 768–772 (1995).
   PubMed Web of Science ®Google Scholar
• Wachsberger P , BurdR, DickerAP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.Clin. Cancer Res.9(6), 1957–1971 (2003).
   PubMed Web of Science ®Google Scholar
• Linkous A , GengL, LyshchikA, HallahanDE, YazlovitskayaEM. Cytosolic phospholipase A2, targeting cancer through the tumor vasculature.Clin. Cancer Res.15(5), 1635–1644 (2009).
   PubMed Web of Science ®Google Scholar
• Yazlovitskaya EM , LinkousAG, ThotalaDK, CuneoKC, HallahanDE. Cytosolic phospholipase A2 regulates viability of irradiated vascular endothelium.Cell Death Differ.15(10), 1641–1653 (2008).
   PubMed Web of Science ®Google Scholar
• Clark JD , LinLL, KrizRWet al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAP. Cell 65(6), 1043–1051 (1991).
   PubMed Web of Science ®Google Scholar
• Hirabayashi T , ShimizuT. Localization and regulation of cytosolic phospholipase A(2).Biochim. Biophys. Acta.1488(1–2), 124–138 (2000).
   PubMed Web of Science ®Google Scholar
• Farooqui AA , OngWY, HorrocksLA. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders.Pharmacol. Rev.58(3), 591–620 (2006).
   PubMed Web of Science ®Google Scholar
• Herbert SP , OdellAF, PonnambalamS, WalkerJH. The confluence-dependent interaction of cytosolic phospholipase A2-α with annexin A1 regulates endothelial cell prostaglandin E2 generation.J. Biol. Chem.282(47), 34468–34478 (2007).
   PubMed Web of Science ®Google Scholar
• Kolesnick R , FuksZ. Radiation and ceramide-induced apoptosis.Oncogene22, 5897–5906 (2003).
   PubMed Web of Science ®Google Scholar
• Haimovitz-Friedman A , KanCC, EhleiterDet al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. Exp. Med. 180, 525–535 (1994).
   PubMed Web of Science ®Google Scholar
• Mikkelsen RB , WardmanP. Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms.Oncogene22, 5734–5754 (2003).
   PubMed Web of Science ®Google Scholar
• Maclachlan T , NarayananB, GerlachVLet al. Human fibroblast growth factor 20 (FGF-20; CG53135–05), a novelcytoprotectant with radioprotective potential. Int. J. Radiat. Biol. 81, 567–579 (2005).
   PubMed Web of Science ®Google Scholar
• Edwards E , GengL, TanJ, OnishkoH, DonnellyE, HallahanDE. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation.Cancer Res.62, 4671–4677 (2002).
   PubMed Web of Science ®Google Scholar
• Tan J , HallahanDE. Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response.Cancer Res.63, 7663–7667 (2003).
   PubMed Web of Science ®Google Scholar
• Cabral GA . Lipids as bioeffectors in the immune system.Life Sci.77, 1699–1710 (2005).
   PubMed Web of Science ®Google Scholar
• Farooqui AA , HorrocksLA. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly.Neuroscientist12, 245–260 (2006).
   PubMed Web of Science ®Google Scholar
• Noor S , GoldfineH, TuckerDEet al. Activation of cytosolic phospholipase A2α in resident peritoneal macrophages by Listeria monocytogenes involves listeriolysin O and TLR2. J. Biol. Chem. 283(8), 4744–4755 (2008).
   PubMed Web of Science ®Google Scholar
• Nakanishi M , RosenbergDW. Roles of cPLA2α and arachidonic acid in cancer.Biochim. Biophys. Acta1761(11), 1335–1343 (2006).
   PubMed Web of Science ®Google Scholar
• Wang D , DuBoisRN. Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer.Gastroenterol. Clin. North Am.39(3), 697–707 (2010).
   PubMed Web of Science ®Google Scholar
• Linkous A , YazlovitskayaE. Cytosolic phospholipase A2 as a mediator of disease pathogenesis.Cell Microbiol.12(10), 1369–1377 (2010).
   PubMed Web of Science ®Google Scholar
• Chakraborti S . Phospholipase A(2) isoforms: a perspective.Cell Signal.15, 637–665 (2003).
   PubMed Web of Science ®Google Scholar
• Fujita Y , YoshizumiM, IzawaYet al. Transactivation of fetal liver kinase-1/kinase-insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation. Endocrinology 147, 1377–1385 (2006).
   PubMed Web of Science ®Google Scholar
• Murugesan G , Sandhya RaniMR, GerberCEet al. Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines. J. Mol. Cell Cardiol.35, 1375–1384 (2003).
   PubMed Web of Science ®Google Scholar
• Sugiyama S , KugiyamaK, OgataNet al. Biphasic regulation of transcription factor nuclear factor-κB activity in human endothelial cells by lysophosphatidylcholine through protein kinase C-mediated pathway. Arterioscler. Thromb. Vasc. Biol. 18, 568–576 (1998).
   PubMed Web of Science ®Google Scholar
• Dent P , YacoubA, FisherPB, HaganMP, GrantS. MAPK pathways in radiation responses.Oncogene22, 5885–5896 (2003).
   PubMed Web of Science ®Google Scholar
• Tan J , GengL, YazlovitskayaEM, HallahanDE. Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3β in irradiated vascular endothelium.Cancer Res.66, 2320–2327 (2006).
   PubMed Web of Science ®Google Scholar
• Dent P , YacoubA, ContessaJet al. Stress and radiation induced activation of multiple intracellular signaling pathways. Radiat. Res. 159, 283–300 (2003).
   PubMed Web of Science ®Google Scholar
• Yazlovitskaya EM , LinkousAG, ThotalaDK, CuneoKC, HallahanDE. Cytosolic phospholipase A2 regulates viability of irradiated vascular endothelium.Cell Death Differ.15(10), 1641–1653 (2008).
   PubMed Web of Science ®Google Scholar
• Folkman J . A new link in ovarian cancer angiogenesis: lysophosphatidic acid and vascular endothelial growth factor expression.J. Natl Cancer Inst.93(10), 734–735 (2001).
   PubMed Web of Science ®Google Scholar
• Kishi Y , OkudairaS, TanakaMet al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting psophosphatidylcholine to lysophosphatidic acid. J. Biol. Chem. 281(25), 17492–17500 (2006).
   PubMed Web of Science ®Google Scholar
• Aoki J . Mechanisms of lysophosphatidic acid production.Semin. Cell Dev. Biol.15(5), 477–489 (2004).
   PubMed Web of Science ®Google Scholar
• Pages G , GirardA, JeannetonOet al. LPA as a paracrine mediator of adipocyte growth and function. Ann. NY Acad. Sci. 905, 159–164 (2000).
   PubMed Web of Science ®Google Scholar
• An S , BleuT, HallmarkOG, GoetzlEJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid.J. Biol. Chem.273, 7906–7910 (1998).
   PubMed Web of Science ®Google Scholar
• Bandoh K , AokiJ, TairaA, TsujimotoM, AraiH, InoueK. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors.FEBS Lett.478(1–2), 159–165 (2000).
   PubMed Web of Science ®Google Scholar
• van Meeteren LA , MoolenaarWH. Regulation and biological activities of the autotaxin-LPA axis.Prog. Lipid Res.46(2), 145–160 (2007).
   PubMed Web of Science ®Google Scholar
• Lange K , KammererM, SaupeFet al. Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res. 68, 6942–6952 (2008).
   PubMed Web of Science ®Google Scholar
• Hecht JH , WeinerJA, PostSR, ChunJ. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex.J. Cell Biol.135(4), 1071–1083 (1996).
   PubMed Web of Science ®Google Scholar
• Schleicher S , ThotalaD, HallahanDE. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of malignant glioma through effects on tumor vasculature.PLoS ONE (2011) (In Press).
   Web of Science ®Google Scholar
• Lee HY , MurataJ, ClairTet al. Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem. Biophys. Res. Comm. 218(3), 714–719 (1996).
   PubMed Web of Science ®Google Scholar
• Umezu-Goto M , TanyiJ, LahadJet al. Lysophosphatidic acid production and action: validated targets in cancer? J. Cell. Biochem. 92(6), 1115–1140 (2004).
   PubMed Web of Science ®Google Scholar
• Yuelling LM , FussB. Autotaxin (ATX), a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties.Biochim. Biophys. Acta1781(9), 525–530 (2008).
   PubMed Web of Science ®Google Scholar
• Croset M , BrossardN, PoletteA, LagardeM. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat.Biochem. J.345Pt 1, 61–67 (2000).
   PubMed Web of Science ®Google Scholar
• Tokumura A , MajimaE, KariyaYet al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277(42), 39436–39442 (2002).
   PubMed Web of Science ®Google Scholar
• Nam SW , ClairT, CampoCK, LeeHY, LiottaLA, StrackeML. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells.Oncogene19(2), 241–247 (2000).
   PubMed Web of Science ®Google Scholar
• Mills GB , MoolenaarWH. The emerging role of lysophosphatidic acid in cancer.Nat. Rev. Cancer.3(8), 582–591 (2003).
   PubMed Web of Science ®Google Scholar
• Baumforth KR , FlavellJR, ReynoldsGMet al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 106(6), 2138–2146 (2005).
   PubMed Web of Science ®Google Scholar
• Nam SW , ClairT, KimYSet al. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 61(18), 6938–6944 (2001).
   PubMed Web of Science ®Google Scholar
• Herbert SP , OdellAF, PonnambalamS, WalkerJH. Activation of cytosolic phospholipase A2-α as a novel mechanism regulating endothelial cell cycle progression and angiogenesis.J. Biol. Chem.284(9), 5784–5796 (2009).
   PubMed Web of Science ®Google Scholar
• Ambesi A , McKeown-LongoPJ. Anastellin, the angiostatic fibronectin peptide, is a selective inhibitor of lysophospholipid signaling.Mol. Cancer Res.7(2), 255–265 (2009).
   PubMed Web of Science ®Google Scholar
• Peyruchaud O . Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer.Anticancer Agents Med. Chem.9(4), 381–391 (2009).
   PubMed Web of Science ®Google Scholar
• McKew JC , FoleyMA, ThakkerPet al. Inhibition of cytosolic phospholipase A2α: hit to lead optimization. J. Med. Chem. 49(1), 135–158 (2006).
   PubMed Web of Science ®Google Scholar
• Fujita Y , YoshizumiM, IzawaYet al. Transactivation of fetal liver kinase-1/kinase-insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation. Endocrinology 147(3), 1377–1385 (2006).
   PubMed Web of Science ®Google Scholar
• Linkous AG , YazlovitskayaEM, HallahanDE. Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis.J. Natl Cancer Inst.102(18), 1398–1412 (2010).
   PubMedGoogle Scholar
• Clamon G , HerndonJ, CooperR, ChangAY, RosenmanJ, GreenMR. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.J. Clin. Oncol.17(1), 4–11 (1999).
   PubMed Web of Science ®Google Scholar
• Lee JH , MachtayM, KaiserLR. et al. Nonsmall cell lung cancer: prognostic factors in patients treated with surgery and postoperative radiation therapy. Radiology213, 845–852 (1999).
   PubMed Web of Science ®Google Scholar
• Magrioti V , KokotosG. Synthetic inhibitors of group IVa and group VIa phospholipase A2. Antiinflamm. Antiallergy Agents Med. Chem.5, 189–203 (2006).
   Google Scholar
• Magrioti V , KokotosG. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Exp. Opin. Ther. Patents20, 1–18 (2010).
   PubMed Web of Science ®Google Scholar
• Amir E , HughesS, BlackhallFet al. Targeting blood vessels for the treatment of non-small cell lung cancer. Curr. Cancer Drug Targets 8, 392–403 (2008).
   PubMed Web of Science ®Google Scholar
• Hoffman PC , MauerAM, VokesEE. Lung cancer.Lancet355, 479–485 (2000).
   PubMed Web of Science ®Google Scholar
• Brock MV , HookerCM, Ota-MachidaEet al. DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 358, 1118–1128 (2008).
   PubMed Web of Science ®Google Scholar
• Shweiki D , NeemanM, ItinA, KeshetE. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis.Proc. Natl Acad. Sci. USA92, 768–772 (2008).
   Google Scholar
• Wachsberger P , BurdR, DickerAP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.Clin. Cancer Res.9, 1957–1971 (2003).
   PubMed Web of Science ®Google Scholar
• Folkman J . Tumor angiogenesis: therapeutic implications.N. Engl. J. Med.285, 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Strijbos MH , GratamaJW, KraanJ, LamersCH, BakkerMA, SleijferS. Circulating endothelial cells in oncology: pitfalls and promises.Br. J. Cancer98, 1731–1735 (2008).
   PubMed Web of Science ®Google Scholar
• Drug Data Report 30(7), 611 (2008).
   Google Scholar
• Laye JP , GillJH. Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discov. Today8, 710–716 (2003).
   PubMed Web of Science ®Google Scholar
• Cummings BS . Phospholipase A2 as targets for anti-cancer drugs.Biochem. Pharmacol.74, 949–959 (2007).
   PubMed Web of Science ®Google Scholar
• Tosato G , SegarraM, SalvucciO. Cytosolic phospholipase A2α and cancer: a role in tumor angiogenesis.J. Natl. Cancer Inst.102, 1377–1379 (2010).
   PubMedGoogle Scholar

Website

• Clinical trials website www.clinicaltrial.gov/
   Google Scholar